Clinicopathological analysis of benign and malignant struma ovarii

doi:10.3969/j.issn.1006-7795.2022.03.003

Abstract

Abstract: Objective To investigate the clinicopathology features of benign and malignant struma ovarii (SO) and analysis the diagnosis and treatment. Methods The ages, symptoms, signs and other general data of 80 patients with benign SO and 13 patients with malignant SO confirmed by surgery and pathology were collected from March 2009 to August 2021 in Beijing Obstetrics and Gynecology Hospital, Capital Medical University and Beijing Chaoyang Integrative Medicine Emergency Medical Center. Ultrasound examination and serum tumor marker test were performed. Both benign and malignant SO patients received surgical treatment. The diagnosis was confirmed by routine postoperative pathological analysis of the gross mass and paraffin hematoxylin-eosin(HE) staining. For malignant patients, The International Federation of Gynecology and Obstetrics (FIGO) staging was performed according to surgical pathology and supplementary treatment was performed according to National Comprehensive Cancer Network (NCCN) guidelines. Results The majority of SO patients did not show obvious clinical symptoms, most of which occurred in unilateral ovary. The ultrasound findings were nonspecific and often showed regular multilocular cystic solid masses. All 13 patients with malignant SO were stage I ovarian thyroid carcinoid. Among the 15 patients who underwent immunohistochemical test, thyroid transcription factor-1(TTF-1) and thyroglobulin (TG) were positive, and Ki67 expression level was low. Only 16 patients (20%) in benign SO had elevated tumor markers, while carbohydrate antigen 199(CA199) levels of 3 patients (23.08%) in malignant SO had slightly elevated. Laparoscopy is the main approach for benign SO surgery, and 41 patients (51.25%) underwent ovarian cystectomy. Transabdominal surgery is the main approach for malignant SO surgery, only 5 cases (38.46%) were performed with ovarian tumor staging, and 4 patients received postoperative supplementary chemotherapy. Conclusion The incidence of SO is low. The clinical manifestations, ultrasound and serum tumor markers are not specific. Patients with ascites are more likely to be confused with epithelial ovarian malignancy. SO profile typically showed multilocular cystic solid, containing gelatinous objects and remote hemorrhage focus, and the texture was not bad and brittle. Surgical resection is the main diagnostic method and treatment.

Key words: struma ovarii, clinicopathology features, diagnosis

CLC Number:

R737.31

Tian Ming, Kong Qiu, Hou Xiaoxiao, Miao Jinwei. Clinicopathological analysis of benign and malignant struma ovarii[J]. Journal of Capital Medical University, 2022, 43(3): 343-349.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.03.003

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I3/343

References

[1] Khatchapuridze K, Kekelidze N, Tsitsishvili Z, et al. Papillary thyroid carcinoma in struma ovarii[J]. Gynecol Endocrinol, 2020, 36(8): 749-752.
[2] McGill J F, Sturgeon C, Angelos P. Metastatic struma ovarii treated with total thyroidectomy and radioiodine ablation[J]. Endocr Pract, 2009, 15(2): 167-173.
[3] Berek J S, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update[J]. Int J Gynaecol Obstet, 2021, 155(Suppl 1): 61-85.
[4] Armstrong D K, Alvarez R D, Bakkum-Gamez J N, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(2): 191-226.
[5] 杨倩, 杨筱, 刘真真, 等. 卵巢甲状腺肿的超声表现及病理特征对照[J]. 中国医学科学院学报, 2015, 37(3): 309-314.
[6] 王晨晨, 宋芳, 肖川, 等. 卵巢甲状腺肿类癌临床病理特征并文献复习[J]. 中华肿瘤防治杂志, 2020, 27(19): 1590-1597.
[7] 徐玉乔, 周汝, 张红娟, 等. 卵巢甲状腺肿的临床病理特征及诊断思路[J]. 中华病理学杂志, 2018, 47(9): 733-736.
[8] 贺琰, 王小燕. 右侧卵巢恶性甲状腺肿子宫附件超声及造影表现1例并文献复习[J]. 中国临床医学影像杂志, 2021, 32(4): 301-303.
[9] Podfigurna A, Szeliga A, Horwat P, et al. Hyperthyroidism associated with struma ovarii-a case report and review of literature[J]. Gynecol Endocrinol, 2021, 37(12): 1143-1150.
[10] Chiang B, Lai R, Mansor S, et al. Metastatic malignant struma ovarii and graves’ disease: a rare occurrence[J]. AACE Clin Case Rep, 2021, 7(4): 243-246.
[11] Fujiwara S, Tsuyoshi H, Nishimura T, et al. Precise preoperative diagnosis of struma ovarii with pseudo-Meigs' syndrome mimicking ovarian cancer with the combination of ¹³¹Ⅰscintigraphy and ¹⁸F-FDG PET: case report and review of the literature[J]. J Ovarian Res, 2018, 11(1): 11.
[12] 丁梦楠, 杨林青, 张玉英, 等. 巨大卵巢甲状腺肿、胸腹腔积液伴糖抗原125显著升高一例[J]. 中国综合临床, 2021, 37(2): 128-130.
[13] Weinberger V, Kadlecova J, Minár∨ L, et al. Struma ovarii-ultrasound features of a rare tumor mimicking ovarian cancer[J]. Med Ultrason, 2018, 20(3): 355-361.
[14] 智明春, 赵学英, 李炜, 等. 25例卵巢甲状腺肿经阴道超声特征分析[J]. 中国病案, 2020, 21(7): 102-105.
[15] 王巧, 姜向阳. 卵巢甲状腺肿并假Meigs综合征与血清CA125升高1例并文献复习[J]. 中国计划生育学杂志, 2020, 28(2): 300-302.
[16] Wei S Z, Baloch Z, Livolsi V. Pathology of struma ovarii: single institutional experience with 93 cases[J]. Am J Clin Pathol, 2015, 144(suppl 2): A302.
[17] Ayhan S, Kilic F, Ersak B, et al. Malignant struma ovarii: from case to analysis[J]. J Obstet Gynaecol Res, 2021, 47(9): 3339-3351.
[18] Lebreton C, Al Ghuzlan A, Floquet A, et al. Thyroid carcinoma on struma ovarii: diagnosis and treatment[J]. Bull Cancer, 2018, 105(3): 281-289.
[19] Davis K P, Hartmann L K, Keeney G L, et al. Primary ovarian carcinoid tumors[J]. Gynecol Oncol, 1996, 61(2): 259-265.
[20] Armes J E, Ostör A G. A case of malignant strumal carcinoid[J]. Gynecol Oncol, 1993, 51(3): 419-423.
[21] Kurabayashi T, Minamikawa T, Nishijima S, et al. Primary strumal carcinoid tumor of the ovary with multiple bone and breast metastases[J]. J Obstet Gynaecol Res, 2010, 36(3): 567-571.
[22] 张晓波, 徐游贵, 沈丹华. 卵巢甲状腺肿类癌临床病理分析[J]. 中华肿瘤防治杂志, 2021, 28(19): 1498-1502.